Erasca, Inc.

ERAS

We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for more than five million new patients diagnosed with …

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$5.21B

EPS-$0.95

P/E-15.69

P/FCF-53.17

EV/EBITDA-16.49

FCF Yield–

Div. Yield–

Net Debt/FCF2.3x

Erasca, Inc. intrinsic value

52-Week Range

$3.00$22.47

Profitability & Returns

TTM as of 2026-06 · YoY vs prior year · ROIC = NOPAT / invested capital

Revenue

N/A

Net Income (TTM)

-$287M

▲ +23.0% YoY

Op. Margin

–

ROIC

-59.24%

▲ +7.2pp YoY

Cash Flow & Balance Sheet

FCF = operating cash flow + capex · Net debt = total debt − cash · Balance sheet from latest filing

FCF (TTM)

-$98M

▲ +12.7% YoY

Op. Cash Flow (TTM)

-$98M

▲ +12.8% YoY

Net Debt

-$224M

Net Cash Position

Cash & Equiv.

$269M

Continue Research

Quality Scorecard

Is this a high-quality business?

Dividends

Payout safety and growth

Intrinsic Value

What is it worth?

Financials

Full income, cash flow, balance sheet

Peers

Pharmaceutical Preparations · Pick stocks to compare with ERAS

CompareIntrinsic value

AARDAardvark Therapeutics, Inc.

$1.26+2.44%10

ORMPOramed Pharmaceuticals Inc.

$4.13+3.25%35

NTHINeonC Technologies Holdings

$3.17+3.26%10

SLNSilence Therapeutics plc

$19.80+0.10%10

SEPNSepterna, Inc.

$47.88+9.57%46

AXSMAxsome Therapeutics, Inc.

$137.00-1.87%10

NKTXNkarta Inc.

$1.73+13.07%10

TNXPTonix Pharmaceuticals Holding Corp

$5.11-1.54%40

Held by ETFs

ERAS is in 57 US ETFs. The largest of them, with ERAS's weight in each:

Erasca (ERAS) in two numbers

Dividend: None; No dividend in the SEC filings we hold.; Dividends
P/E: -15.69; Negative: a loss over the last twelve months. Price to free cash flow -53.17.; Financials

Questions about Erasca

Does Erasca (ERAS) pay a dividend?

No. Erasca (ERAS) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 4 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in ERAS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ERAS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.